The graduate program in pharmacotherapy is designed to develop an individual who is educated and trained to conduct translational research integrating both science and practice. The graduate will be able to independently engage in the discovery, dissemination and application of pharmaceutical and biomedical knowledge to improve the health status of society.
Graduate CompetenciesA graduate from the program will be:
The curriculum will include rigorous course work and practical training in scientific methods and an area of specialized practice. The academic and research program are tailored to meet a student's specific interests and professional goals and are decided upon by the student and the supervising professor. The curriculum will include core and elective courses deemed essential to develop comprehensive knowledge and skills in the selected area of investigation. Core courses include advanced biostatistics, two semesters of pharmacodynamics, pharmaceutical analysis, molecular biology, research design and methods, and ethics in research and practice.
Applicants should hold a baccalaureate or Pharm.D. degree from a College of Pharmacy accredited by the American Council on Pharmaceutical Education. In addition to the usual graduate school admission criteria, applicants are evaluated on their potential for creative thought, independent work and scholarship in clinical pharmacy research and practice as assessed by letters of recommendation and prior accomplishments; ability to communicate effectively with scientific and professional colleagues as assessed by personal interview, personal statement and letters of recommendation; and professional practice experience.
Education & Research Ctr.
College of Pharmacy
The University of Texas
Health Science Center
7703 Floyd Curl Drive - MC 6220
San Antonio, TX
Email Address: pharmacy
Dr. Kelly Reveles, assistant professor of pharmacotherapy, is primary author of a study which found that the incidence of Clostridium difficile infection (CDI), a highly contagious gastrointestinal disease often linked to the overprescribing of antibiotics, nearly doubled between 2001 and 2010. It also determined there were no improvements in patient health outcomes, including mortality or hospital length of stay, over the study period.